From: Screening of Natural Compounds for CYP11A1 Stimulation Against Cell Renal Cell Carcinoma
HPLC gradient | |||||
Time (min) | Mobile A (%) | Mobile B (%) | Flow rate (mL/min) | ||
0 | 100 | 0 | 0.4 | ||
1 | 75 | 25 | 0.4 | ||
2 | 50 | 50 | 0.4 | ||
6 | 0 | 100 | 0.4 | ||
7.5 | 0 | 100 | 0.4 | ||
8 | 100 | 0 | 0.4 | ||
10 | 100 | 0 | 0.4 | ||
MS operating condition | |||||
Mode | ESI positive mode | ||||
Scan type | Full scan or multi reaction monitoring | ||||
Compounds | MW | [M + H]+ | Ion transition | Collision energy | Retention time (min) |
Cholesterol | 386.65 | 369.35 | 369.35 → 243.15 | 35 | 6.67 |
Pregnenolone | 316.48 | 299.26 | 299.26 → 281.23 | 35 | 4.49 |
Finastride (IS) | 372.54 | 373.28 | 373.28 → 305.22 | 35 | 4.14 |